April 2016 in “Journal of Investigative Dermatology” This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.
4 citations
,
November 2024 in “International Journal of Biological Macromolecules” In this study, the researchers developed a cellulose nanofiber-based scaffold containing sitagliptin and zinc sulfide nanoparticles, which promoted scarless healing and hair follicle regeneration in rats by targeting DPP4+ fibroblasts, suggesting a novel approach for improved wound healing and skin regeneration.
April 2019 in “Journal of Investigative Dermatology” This study found that DPP4 is significantly involved in matrix deposition and fibrosis in human skin fibroblasts, although the exact functions of DPP4 remain unclear.
2 citations
,
November 2020 in “Der Hautarzt” This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” This case report describes a 68-year-old man who developed both alopecia areata and bullous pemphigoid after starting linagliptin for diabetes, suggesting a possible link with DPP-4 inhibitors.